Peptide-decorated polymeric nanomedicines for precision cancer therapy

Huanli Sun, Yangyang Dong, Jan Feijen, Zhiyuan Zhong (Corresponding Author)

Research output: Contribution to journalArticleAcademicpeer-review

7 Citations (Scopus)
128 Downloads (Pure)

Abstract

The advancement of tissue and cell-specific drug delivery systems is a key to precision cancer therapy. Peptides, with easy synthesis, low immunogenicity and biological functions closely mimicking or surpassing natural proteins, have been actively engineered and explored to provide nanomedicines with the ability to overcome various extracellular and intracellular delivery barriers ranging from phagocytic clearance in the circulation, low tumor penetration, poor cancer cell selectivity, inferior cell penetration, to endosomal entrapment as well as poor blood brain barrier permeation for brain cancer therapy. Anti-tumor studies with peptide-decorated polymeric nanomedicines are currently in the experimental stage. Most of the reported peptide-directed polymeric nanomedicines do have a rather complex design requiring a multi-step reproducible fabrication process. Moreover, many of the proposed peptide-decorated polymeric nanomedicines are still not able to effectively overcome the drug delivery cascade barriers. Consequently, in order to facilitate clinical translation the complexity of the systems has to be reduced, while maintaining the added functions after the introduction of the different peptides and further progress has to be made in passing the various drug delivery barriers. In this review, we give an overview of the rational design, development and preclinical performance of peptide-decorated polymeric nanomedicines, and further discuss their challenges and future perspectives as a next generation cancer treatment modality.

Original languageEnglish
Pages (from-to)11-27
Number of pages17
JournalJournal of controlled release
Volume290
DOIs
Publication statusPublished - 28 Nov 2018

Fingerprint

Nanomedicine
Peptides
Neoplasms
Therapeutics
Drug Delivery Systems
Blood-Brain Barrier
Brain Neoplasms
Pharmaceutical Preparations

Keywords

  • UT-Hybrid-D
  • Peptide
  • Polymeric nanomedicines
  • Therapeutic delivery
  • Cancer therapy

Cite this

Sun, Huanli ; Dong, Yangyang ; Feijen, Jan ; Zhong, Zhiyuan. / Peptide-decorated polymeric nanomedicines for precision cancer therapy. In: Journal of controlled release. 2018 ; Vol. 290. pp. 11-27.
@article{dd8bc99d2d69496a809db6704f713a04,
title = "Peptide-decorated polymeric nanomedicines for precision cancer therapy",
abstract = "The advancement of tissue and cell-specific drug delivery systems is a key to precision cancer therapy. Peptides, with easy synthesis, low immunogenicity and biological functions closely mimicking or surpassing natural proteins, have been actively engineered and explored to provide nanomedicines with the ability to overcome various extracellular and intracellular delivery barriers ranging from phagocytic clearance in the circulation, low tumor penetration, poor cancer cell selectivity, inferior cell penetration, to endosomal entrapment as well as poor blood brain barrier permeation for brain cancer therapy. Anti-tumor studies with peptide-decorated polymeric nanomedicines are currently in the experimental stage. Most of the reported peptide-directed polymeric nanomedicines do have a rather complex design requiring a multi-step reproducible fabrication process. Moreover, many of the proposed peptide-decorated polymeric nanomedicines are still not able to effectively overcome the drug delivery cascade barriers. Consequently, in order to facilitate clinical translation the complexity of the systems has to be reduced, while maintaining the added functions after the introduction of the different peptides and further progress has to be made in passing the various drug delivery barriers. In this review, we give an overview of the rational design, development and preclinical performance of peptide-decorated polymeric nanomedicines, and further discuss their challenges and future perspectives as a next generation cancer treatment modality.",
keywords = "UT-Hybrid-D, Peptide, Polymeric nanomedicines, Therapeutic delivery, Cancer therapy",
author = "Huanli Sun and Yangyang Dong and Jan Feijen and Zhiyuan Zhong",
note = "Elsevier deal",
year = "2018",
month = "11",
day = "28",
doi = "10.1016/j.jconrel.2018.09.029",
language = "English",
volume = "290",
pages = "11--27",
journal = "Journal of controlled release",
issn = "0168-3659",
publisher = "Elsevier",

}

Peptide-decorated polymeric nanomedicines for precision cancer therapy. / Sun, Huanli; Dong, Yangyang; Feijen, Jan; Zhong, Zhiyuan (Corresponding Author).

In: Journal of controlled release, Vol. 290, 28.11.2018, p. 11-27.

Research output: Contribution to journalArticleAcademicpeer-review

TY - JOUR

T1 - Peptide-decorated polymeric nanomedicines for precision cancer therapy

AU - Sun, Huanli

AU - Dong, Yangyang

AU - Feijen, Jan

AU - Zhong, Zhiyuan

N1 - Elsevier deal

PY - 2018/11/28

Y1 - 2018/11/28

N2 - The advancement of tissue and cell-specific drug delivery systems is a key to precision cancer therapy. Peptides, with easy synthesis, low immunogenicity and biological functions closely mimicking or surpassing natural proteins, have been actively engineered and explored to provide nanomedicines with the ability to overcome various extracellular and intracellular delivery barriers ranging from phagocytic clearance in the circulation, low tumor penetration, poor cancer cell selectivity, inferior cell penetration, to endosomal entrapment as well as poor blood brain barrier permeation for brain cancer therapy. Anti-tumor studies with peptide-decorated polymeric nanomedicines are currently in the experimental stage. Most of the reported peptide-directed polymeric nanomedicines do have a rather complex design requiring a multi-step reproducible fabrication process. Moreover, many of the proposed peptide-decorated polymeric nanomedicines are still not able to effectively overcome the drug delivery cascade barriers. Consequently, in order to facilitate clinical translation the complexity of the systems has to be reduced, while maintaining the added functions after the introduction of the different peptides and further progress has to be made in passing the various drug delivery barriers. In this review, we give an overview of the rational design, development and preclinical performance of peptide-decorated polymeric nanomedicines, and further discuss their challenges and future perspectives as a next generation cancer treatment modality.

AB - The advancement of tissue and cell-specific drug delivery systems is a key to precision cancer therapy. Peptides, with easy synthesis, low immunogenicity and biological functions closely mimicking or surpassing natural proteins, have been actively engineered and explored to provide nanomedicines with the ability to overcome various extracellular and intracellular delivery barriers ranging from phagocytic clearance in the circulation, low tumor penetration, poor cancer cell selectivity, inferior cell penetration, to endosomal entrapment as well as poor blood brain barrier permeation for brain cancer therapy. Anti-tumor studies with peptide-decorated polymeric nanomedicines are currently in the experimental stage. Most of the reported peptide-directed polymeric nanomedicines do have a rather complex design requiring a multi-step reproducible fabrication process. Moreover, many of the proposed peptide-decorated polymeric nanomedicines are still not able to effectively overcome the drug delivery cascade barriers. Consequently, in order to facilitate clinical translation the complexity of the systems has to be reduced, while maintaining the added functions after the introduction of the different peptides and further progress has to be made in passing the various drug delivery barriers. In this review, we give an overview of the rational design, development and preclinical performance of peptide-decorated polymeric nanomedicines, and further discuss their challenges and future perspectives as a next generation cancer treatment modality.

KW - UT-Hybrid-D

KW - Peptide

KW - Polymeric nanomedicines

KW - Therapeutic delivery

KW - Cancer therapy

UR - http://www.scopus.com/inward/record.url?scp=85054511321&partnerID=8YFLogxK

U2 - 10.1016/j.jconrel.2018.09.029

DO - 10.1016/j.jconrel.2018.09.029

M3 - Article

VL - 290

SP - 11

EP - 27

JO - Journal of controlled release

JF - Journal of controlled release

SN - 0168-3659

ER -